The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterised by widespread loss of central cholinergic function. The only symptomatic treatment proven effective to date is the use of cholinesterase (ChE) inhibitors to augment surviving cholinergic activity. ChE inhibitors act on the enzymes that hydrolyse acetylcholine (ACh) following synaptic release. In the healthy brain, acetylcholinesterase (AChE) predominates (80%) and butyrylcholinesterase (BuChE) is considered to play a minor role in regulating brain ACh levels. In the AD brain, BuChE activity rises while AChE activity remains unchanged or declines. Therefore both enzymes are likely to have involvement in regulating ACh levels and represent legitimate therapeutic targets to ameliorate the cholinergic deficit. The two enzymes differ in location, substrate specificity and kinetics. Recent evidence suggests that BuChE may also have a role in the aetiology and progression of AD beyond regulation of synaptic ACh levels. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. The development of specific BuChE inhibitors and the continued use of ChE inhibitors with the ability to inhibit BuChE in addition to AChE should lead to improved clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states
Quinn, D. M. (1987) · Chemical Reviews · doi:10.1021/cr00081a005 · Cited by 1,072
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
Cited by
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Howes, M. R., Perry, N. S. L., & Houghton, P. J. (2003) · Phytotherapy Research · doi:10.1002/ptr.1280 · Cited by 416
Mushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331
Self-citationScheiner, M., Dolles, D., Gunesch, S., Hoffmann, M., Nabissi, M., Marinelli, O., Naldi, M., Bartolini, M., Petralla, S., Poeta, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00623 · Cited by 49
Metadata
- Authors
- Greig, N. H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H. W., Perry, T., Lee, B., Ingram, D. K., & Lahiri, D. K.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2001-11-23
- Volume
- 17
- Issue
- 3
- Pages
- 159-165
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W4248650858
- Cited by
- 493
- References
- 2
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase. https://app.cochat.ai/papers/10.1185/03007990152673800
- The paper
- Greig, N. H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H. W., Perry, T., Lee, B., Ingram, D. K., & Lahiri, D. K. (2001). A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase. Current Medical Research and Opinion. https://doi.org/10.1185/03007990152673800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.